178 related articles for article (PubMed ID: 38497108)
1. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
Palaia I; Caruso G; Di Donato V; Turetta C; Savarese A; Perniola G; Gallo R; Giannini A; Salutari V; Bogani G; Tomao F; Giannarelli D; Gentile G; Musella A; Muzii L; Pignata S;
J Gynecol Oncol; 2024 May; 35(3):e70. PubMed ID: 38497108
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
3. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
Perri T; Farhadian Y; Friedman E; Korach J
Menopause; 2020 Jan; 27(1):82-87. PubMed ID: 31688415
[TBL] [Abstract][Full Text] [Related]
7. Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
[TBL] [Abstract][Full Text] [Related]
8. Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines-a survey in Sweden.
Halldorsdottir S; Dahlstrand H; Stålberg K
Ups J Med Sci; 2018 Dec; 123(4):225-229. PubMed ID: 30526173
[TBL] [Abstract][Full Text] [Related]
9. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
[TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
Loizzi V; Dellino M; Cerbone M; Arezzo F; Chiariello G; Lepera A; Cazzato G; Cascardi E; Damiani GR; Cicinelli E; Cormio G
Hormones (Athens); 2023 Mar; 22(1):19-23. PubMed ID: 36637775
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
[TBL] [Abstract][Full Text] [Related]
12. A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.
Gavaruzzi T; Tasso A; Franiuk M; Varesco L; Lotto L
J Genet Couns; 2017 Oct; 26(5):1144-1152. PubMed ID: 28337671
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
14. Hormone Replacement Therapy Prescription after Premature Surgical Menopause.
Garg N; Behbehani S; Kosiorek H; Wasson M
J Minim Invasive Gynecol; 2020; 27(7):1618-1623. PubMed ID: 32173578
[TBL] [Abstract][Full Text] [Related]
15. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
16. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
17. Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
Johansen N; Liavaag AH; Iversen OE; Dørum A; Braaten T; Michelsen TM
Acta Obstet Gynecol Scand; 2017 May; 96(5):547-555. PubMed ID: 28236297
[TBL] [Abstract][Full Text] [Related]
18. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
[TBL] [Abstract][Full Text] [Related]
19. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
[TBL] [Abstract][Full Text] [Related]
20. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]